2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2112

IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2111

Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 1985

IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2052

Immune Therapy of Rheumatoid Arthritis Patients with a Microbiome-Derived, Self/Non-Self Peptide Induces Clinically Relevant Immune Tolerance Pivoting on Immune Checkpoint-Expressing, Therapy-Induced Tregs

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2042

Immunophenotypic Analysis of Tissue-Resident Memory T Cells in Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2541

Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2164

IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2534

Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2566

Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2503

Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2044

Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2309

Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2304

Implication of Bone Turnover Marker Follow-up during Antiresorptive Therapy in Patients with Active Rheumatoid Arthritis on Immunosuppresssive Agents

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2294

Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2489

In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].